Shares of Allogene Therapeutics Inc (NASDAQ:ALLO) have received a consensus rating of “Buy” from the thirteen ratings firms that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $36.22.
A number of brokerages have issued reports on ALLO. Zacks Investment Research cut shares of Allogene Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. Roth Capital began coverage on shares of Allogene Therapeutics in a research note on Wednesday, June 5th. They issued a “neutral” rating and a $26.00 price objective on the stock. Stifel Nicolaus began coverage on shares of Allogene Therapeutics in a research note on Wednesday, May 22nd. They issued a “hold” rating and a $27.00 price objective on the stock. Oppenheimer began coverage on shares of Allogene Therapeutics in a research note on Friday, May 3rd. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $29.00 price objective on shares of Allogene Therapeutics in a research note on Sunday.
Shares of ALLO traded down $0.69 during mid-day trading on Friday, hitting $26.94. 7,736 shares of the company traded hands, compared to its average volume of 317,936. Allogene Therapeutics has a one year low of $21.67 and a one year high of $35.55. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.46 and a quick ratio of 13.46. The business has a 50-day simple moving average of $28.30. The stock has a market capitalization of $3.59 billion and a PE ratio of -4.20.
In other Allogene Therapeutics news, insider Alison Moore sold 48,827 shares of the stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $29.44, for a total value of $1,437,466.88. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 36.50% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Nuveen Asset Management LLC acquired a new stake in Allogene Therapeutics in the second quarter worth $14,967,000. UBS Asset Management Americas Inc. raised its holdings in Allogene Therapeutics by 1.1% in the second quarter. UBS Asset Management Americas Inc. now owns 200,267 shares of the company’s stock worth $5,377,000 after purchasing an additional 2,142 shares during the period. Wildcat Capital Management LLC acquired a new stake in Allogene Therapeutics in the second quarter worth $14,289,000. Jefferies Group LLC acquired a new stake in Allogene Therapeutics in the second quarter worth $752,000. Finally, Morgan Stanley raised its holdings in Allogene Therapeutics by 7.7% in the second quarter. Morgan Stanley now owns 9,707 shares of the company’s stock worth $260,000 after purchasing an additional 691 shares during the period. Institutional investors own 51.30% of the company’s stock.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Recommended Story: Are we seeing the beginning of a new bubble?
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.